85P Long-term follow-up of a regional molecular tumor board: Alignment with the ESMO Precision Oncology Working Group recommendations

C. Van Marcke; M. Simon; A. Thomas; A-F. Dekairelle; C. Mjoti; D. Croes; L. Duck; F. Collette; C. Quaghebeur; D. Schröder; F. Dall'Armellina; S. Abbeel; S. Ocak; Ivan Borbath; A. Francois; Emmanuel Seront; Marc Van den Eynde; Rachel Galot; F.P. Duhoux; Natasha Honoré

doi:10.1016/j.esmoop.2026.108461

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Clinical interpretation of next-generation sequencing (NGS) results in tumor samples is increasingly complex. Regional molecular tumor boards (MTB) that systematically review all NGS results and identify clinically actionable alterations offer a pragmatic solution to standardize decision-making across institutions and derive real-world data regarding their value.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marcke et al. (2026) studied this question.

synapsesocial.com/papers/6af71b2d01e7bd3bc09a4f45 https://doi.org/10.1016/j.esmoop.2026.108461

View Full Paper

Ask AI

Bookmark

Share

85P Long-term follow-up of a regional molecular tumor board: Alignment with the ESMO Precision Oncology Working Group recommendations

Ask about this paper

Abstract

Discussion

Cite This Study

85P Long-term follow-up of a regional molecular tumor board: Alignment with the ESMO Precision Oncology Working Group recommendations

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading